Cynthia X. Ma, MD, PhD, on Clinical Implications of Findings on Neoadjuvant Endocrine Treatment for ER+ HER2– Breast Cancer

Posted: Monday, June 15, 2020

Cynthia X. Ma, MD, PhD, of Washington University, discusses the results of the ALTERNATE trial and whether anastrozole as a neoadjuvant approach is acceptable to most patients. Dr. Ma also addresses the possible value of using a combination of neoadjuvant treatment plus a prognostic tool to determine whether adjuvant treatment may be omitted in a patient with early-stage estrogen receptor–positive, HER2-negative breast cancer.